Clinical Trial Update: Chemoradiotherapy in Unresectable Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating chemoradiotherapy with nab-paclitaxel for unresectable esophageal cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Esophageal Cancer, Chemoradiotherapy | Phase 1, Phase 2 | Status: RECRUITING